ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis


Tacrolimus (Tac) is effective in the treatment of steroid-refractory ulcerative colitis (UC); however, nonresponse and unpredictable side effects are major limitations. Because Tac response in patients who have undergone solid-organ transplantation has been associated with the presence of variants in CYP3A and ABCB1, we elucidated the contributions of CYP3A4*1B and CYP3A5*3 and of ABCB1 1236C>T, 2677G>T,A, and 3435C>T polymorphisms to Tac response in 89 patients with UC. Short-term remission and response were achieved in 61 and 14% of the patients, respectively, and were associated with colectomy-free survival. In a linear logistic regression model, patients with homozygous variants for one of the three ABCB1 alleles showed significantly higher short-term remission rates as compared with those of other genotypes. The effects held true after multivariate analysis including multiple comparisons and were more pronounced after correction for dose-adjusted Tac blood trough levels. We suggest that ABCB1, but not CYP3A5, may predict short-term remission of Tac in steroid-refractory UC.


Projects: G2: Clinical Translation to Non-Invasive Volunteer Setting

Clin. Pharmacol. Ther.
Clin. Pharmacol. Ther. 89(3): 422-8
2nd Feb 2011

K R Herrlinger, H Koc, S Winter, A Teml, E F Stange, K Fellermann, P Fritz, M Schwab, E Schaeffeler

help Authors

[Matthias Schwab]

help Attributions


help Scales

Not Specified
Views: 1965
  • Created: 18th Jul 2012 at 12:30
  • Last updated: 24th Oct 2013 at 16:19

Related items


Log in / Register

Need an account?
Sign up

Forgotten password?

Front Page

Virtual Liver Network


Related Projects and friends

Imprint Taverna workflow workbench myExperiment JWS Online ISATAB myGrid Sabio-RK BioPortal Semantic SBML

Powered by:


Silk icons 1.3
Crystal Clear icons

Virtual Liver Seek uses one essential cookie to keep you session open and one cookie to keep your consent.

By continuing to use this site you agree to the use of cookies